Impact of a household-level deductible on prescription drug use among lower-income adults: a quasi-experimental study
MR Law, L Cheng, H Worthington… - … Open Access Journal, 2019 - cmajopen.ca
Background: Several Canadian public drug plans have income-based deductibles, but we
have limited data on their impact, particularly for vulnerable populations. Therefore, we …
have limited data on their impact, particularly for vulnerable populations. Therefore, we …
Impact of income-based deductibles on drug use and health care utilization among older adults
MR Law, L Cheng, H Worthington, M Mamdani… - CMAJ, 2017 - Can Med Assoc
BACKGROUND: Income-based deductibles are present in several provincial public drug
plans in Canada and have been the subject of extensive debate. We studied the impact of …
plans in Canada and have been the subject of extensive debate. We studied the impact of …
Distributional Effects of “Needs-Based” Drug Subsidies: Regional Evidence from Canada
P Grootendorst, J Racine - 2006 - tspace.library.utoronto.ca
Canadian provincial government drug subsidy programs have recently begun to change the
basis of subsidy from age (age 65+) to financial need (defined as high drug costs relative to …
basis of subsidy from age (age 65+) to financial need (defined as high drug costs relative to …
The effect of reinsuring a deductible on pharmaceutical spending: A Dutch case study on low-income people
Many countries have cost sharing schemes in health insurance to control health care
expenditures. The Dutch basic health insurance includes a mandatory deductible of …
expenditures. The Dutch basic health insurance includes a mandatory deductible of …
[HTML][HTML] Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data
L McLeod, BG Bereza, M Shim, P Grootendorst - Open Medicine, 2011 - ncbi.nlm.nih.gov
Background Commentaries on the adequacy of insurance coverage for prescription drugs
available to Canadians have emphasized differences in the coverage provided by different …
available to Canadians have emphasized differences in the coverage provided by different …
Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy
Background: Evaluating the adequacy of Medicare prescription drug program (Part D) and
its low-income subsidy (LIS) requires a comprehensive understanding of drug spending in …
its low-income subsidy (LIS) requires a comprehensive understanding of drug spending in …
The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada
OBJECTIVES: To explore the redistributive impact of two different pharmaceutical financing
policies (age-based versus income-based pharmacare) on the distribution of income in …
policies (age-based versus income-based pharmacare) on the distribution of income in …
Persistence and concentration of prescription drug expenditure among Medicare beneficiaries 2006-2013
Y Xu, G Joyce - Value in Health, 2017 - valueinhealthjournal.com
Objectives The rapid growth of prescription drug spending is a major concern for US
policymakers. In 2016, prescription drugs accounted for over 16% of total health care …
policymakers. In 2016, prescription drugs accounted for over 16% of total health care …
[BOOK][B] Deductibles and the demand for prescription drugs: evidence from french data
B Kambia-Chopin, M Perronnin - 2013 - irdes.fr
On January 1st 2008, a 0.5€ deductible levied on every prescription drug package
purchased was introduced in France. This study aims at shedding light on the effect of this …
purchased was introduced in France. This study aims at shedding light on the effect of this …
Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
BACKGROUND: Medicare Part D was expected to have differential impacts on patient drug
expenditures and use based on beneficiaries' levels of pre-Part D patient drug spending, but …
expenditures and use based on beneficiaries' levels of pre-Part D patient drug spending, but …